Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
September 30, 2015 at 09:03 AM EDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in ...